Robert W. Baird reaffirmed their neutral rating on shares of Amgen, Inc. (NASDAQ:AMGN) in a report published on Friday. Robert W. Baird currently has a $165.00 target price on the medical research company’s stock.
AMGN has been the topic of a number of other research reports. Leerink Swann set a $163.00 price objective on Amgen and gave the stock a hold rating in a research note on Monday, November 21st. BMO Capital Markets reaffirmed a buy rating and set a $197.00 target price on shares of Amgen in a research report on Monday, January 9th. Credit Suisse Group AG lowered Amgen from an outperform rating to a neutral rating and cut their target price for the stock from $200.00 to $180.00 in a research report on Tuesday, December 20th. They noted that the move was a valuation call. Zacks Investment Research lowered Amgen from a hold rating to a sell rating in a research report on Tuesday, January 3rd. Finally, Cann reaffirmed an outperform rating and set a $189.00 target price on shares of Amgen in a research report on Tuesday, February 28th. One analyst has rated the stock with a sell rating, ten have assigned a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has an average rating of Buy and an average price target of $187.41.
Shares of Amgen (NASDAQ:AMGN) traded down 6.032% during mid-day trading on Friday, reaching $169.245. The company’s stock had a trading volume of 26,970,039 shares. Amgen has a 52-week low of $133.64 and a 52-week high of $184.21. The firm’s 50 day moving average is $171.88 and its 200-day moving average is $159.86. The company has a market capitalization of $124.64 billion, a PE ratio of 16.528 and a beta of 1.15.
Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Thursday, February 2nd. The medical research company reported $2.89 EPS for the quarter, topping the Zacks’ consensus estimate of $2.79 by $0.10. Amgen had a return on equity of 29.42% and a net margin of 33.59%. The company had revenue of $5.97 billion for the quarter, compared to the consensus estimate of $5.75 billion. During the same quarter in the previous year, the business earned $2.61 EPS. The company’s quarterly revenue was up 7.7% compared to the same quarter last year. Analysts forecast that Amgen will post $12.31 EPS for the current year.
Your IP Address:
The firm also recently declared a quarterly dividend, which will be paid on Thursday, June 8th. Investors of record on Wednesday, May 17th will be given a dividend of $1.15 per share. The ex-dividend date of this dividend is Monday, May 15th. This represents a $4.60 dividend on an annualized basis and a yield of 2.73%. Amgen’s dividend payout ratio (DPR) is presently 44.92%.
A number of large investors have recently added to or reduced their stakes in the company. New York Life Trust Co. raised its stake in Amgen by 54.8% in the third quarter. New York Life Trust Co. now owns 624 shares of the medical research company’s stock worth $104,000 after buying an additional 221 shares during the period. Penserra Capital Management LLC raised its stake in Amgen by 100.0% in the third quarter. Penserra Capital Management LLC now owns 684 shares of the medical research company’s stock worth $114,000 after buying an additional 342 shares during the period. Thomas J. Herzfeld Advisors Inc. acquired a new stake in Amgen during the fourth quarter worth approximately $102,000. Oakworth Capital Inc. raised its stake in Amgen by 1.4% in the third quarter. Oakworth Capital Inc. now owns 711 shares of the medical research company’s stock worth $119,000 after buying an additional 10 shares during the period. Finally, Focused Wealth Management Inc raised its stake in Amgen by 248.0% in the fourth quarter. Focused Wealth Management Inc now owns 870 shares of the medical research company’s stock worth $127,000 after buying an additional 620 shares during the period. Institutional investors and hedge funds own 79.04% of the company’s stock.
Amgen Company Profile
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.